FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

In Phase III, Gardasil prevents HPV in men

Tools

It looks like Gardasil may not just be for girls anymore: a Phase III study of Merck's HPV vaccine found that the jab prevented 90 percent of external genital lesions caused by the disease men aged 16 to 26. In a study of 4,000 men, only three subjects who got the shot developed lesions; there were 31 cases in the placebo group. Gardasil prevents lesions caused by types 6, 11, 16 and 18

Merck said that the company remains on track to submit an sBLA for Gardasil for use in men by the end of 2008. The findings were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference.

- see Merck's release
- read the WSJ blog post

Related Articles:
HPV researcher calls for vaccination of males
What's stopping girls from getting the HPV jab?
Critics accuse Merck of hyping cervical cancer risk
FDA grants Gardasil two new indications

More stories about Vaccine   Merck   Gardasil   Clinical Trial Results  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.